Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhuzigantai Pian is a Traditional Chinese Medicine (TCM) tablet developed by Xishuangbanna Yulin Pharmaceutical Co., Ltd. for the treatment of Hepatitis B. The formulation contains herbal ingredients including sagegrass (*Phyllanthus urinaria*), green leaf gall (*Swertia mileensis*), astragalus (*Astragalus membranaceus*), and licorice (*Glycyrrhiza uralensis*). According to TCM principles, it is indicated for clearing away heat and dampness, replenishing qi, and strengthening the liver, specifically targeting spleen-deficiency and damp-heat symptoms such as chest pain, fatigue, and loose stools associated with chronic Hepatitis B. The drug is administered orally and has received regulatory approval in China (National Medicine Zhunzi Z20026111).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhuzigantai Pian.